Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting BRAF in advanced melanoma: a first step toward manageable disease.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2011

Vultur Adina, Villanueva Jessie, Herlyn Meenhard

Abstract excerpt

Melanoma is the deadliest form of skin cancer and its incidence has been increasing worldwide. The disease manifests itself as clinically and genetically distinct subgroups, indicating the need for patient-specific diagnostic and treatment tools. The discovery of activating mutations (V600E) in the BRAF kinase in approximately 50% of patients spurred the development of compounds to inhibit aberrant BRAF activity,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 21447722
DOI: 10.1158/1078-0432.CCR-10-0174
PMCID: PMC3079374

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting BRAF in advanced melanoma: a first step toward manageable disease.PMID 21447722Read ↗

Emerging targeted therapies for melanoma.Semantic proximity Read ↗

BRAF targeted therapy changes the treatment paradigm in melanoma.Semantic proximity Read ↗

Inhibition of mutated, activated BRAF in metastatic melanoma.Semantic proximity Read ↗

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.Semantic proximity Read ↗

Targeted therapeutic strategies for melanoma.Semantic proximity Read ↗

Major therapeutic developments and current challenges in advanced melanoma.Semantic proximity Read ↗

Immunotherapy in Melanoma: A Dynamic Frontier in Cancer Treatment : Author List.Semantic proximity Read ↗

Targeting BRAF in melanoma: biological and clinical challenges.Semantic proximity Read ↗

Targeted therapy for melanoma: a primer.Semantic proximity Read ↗

The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidenceSemantic proximity Read ↗

Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials.Semantic proximity Read ↗

Personalized therapy in oncology: melanoma as a paradigm for molecular-targeted treatment approaches.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.